🔗 Share this article

Given that the US proceeds with sweeping adjustments to its vaccine recommendations, a particular individual has emerged unexpectedly: Dr. Tracy Beth Høeg, a Danish American sports physician and epidemiologist who first made her name by expressing skepticism about COVID-19 vaccinations during the global health crisis and has zeroed in on potential deaths after Covid immunization in her brief position at the FDA.

Scheduled Changes to Pediatric Vaccine Schedule

Public health authorities had intended to unveil major revisions to the childhood vaccine schedule in December, aligning the US with Denmark’s vaccine program, it is understood – a significant shift that would place the US out of step with much of the international standard with no evidence for benefit. The announcement has been delayed until the next year.

In place of the top vaccines chief, Tracy Beth Høeg is scheduled to address the audience at the gathering. She was recently named temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the center this calendar year.

Consolidating Power at the Regulatory Body

Høeg's temporary position might represent a closer partnership between the drug and vaccine branches as Høeg and Dr. Prasad strengthen their influence at the FDA – and it suggests a renewed priority upon rolling back long-standing immunizations at the FDA.

The new acting director has often pushed for halting some childhood vaccine recommendations in the US so as to align more like the Danish model, a country with universal health coverage and a number of inhabitants roughly the population of Wisconsin’s.

In her initial public appearances, she has persisted in emphasizing on vaccination policy – usually the responsibility of Prasad, director of the FDA’s vaccine center – rather than pharmaceutical oversight.

Concerns Over Qualifications

Dr. Høeg has little discernible experience in pharmaceutical research, oversight or leadership, which has been typical for past leaders of the Center for Biologics Evaluation and Research. She has served at the FDA as a senior adviser to the agency head and CBER since earlier this year.

“It seems she lacks to have the requisite experience” for overseeing the drug-regulation department, said a neurologist and psychiatrist. “She’s never run a clinical trial. She has no expertise in managing a sizeable institution. She has no expertise in industry regulation.”

Former heads of CBER would “grasp regulatory frameworks and the science of medication creation”, said Dr. Janet Woodcock. “Clearly, she doesn’t have the kind of background that former directors who ran CBER have had.”

CDER has an enormous workload at the agency, she emphasized.

“Everybody just zeroes in on the novel medication approvals, but the off-patent medication office clears numerous generic drugs. There is also a biosimilars program, non-prescription drug unit and so forth, and each of these need to be managed,” Woodcock said. “The area you overlook, that’s the thing that I always told people is going to bite you.”

Additionally, a major administrative element to the job, which manages in excess of 5,000 personnel. “It is a enormous management job, if you execute it properly,” Woodcock added.

Agency Reaction and Disputed Policies

When asked about questions about Høeg’s fitness for the role and whether this appointment represents increased cooperation among regulatory chiefs on immunizations, a spokesperson stated that the “inquiries stem from incorrect presumptions”.

“Her resume matches the responsibilities of her position,” the spokesperson explained, citing the months Dr. Høeg spent advising the agency head on “drug safety and approval science, including predictive safety algorithms and immunization monitoring”.

As the temporary head, Høeg inherits the commissioner’s controversial fast-track approval initiative, a contentious rapid medication authorization process that reportedly troubled her predecessors. “By what process are these drugs being selected for this fast-track system? Who is making the decisions?” Dr. Howard asked. “There is a lot of lack of transparency going on at the FDA right now.”

Broadly speaking, he said, “the agency appears to be shifting towards more relaxed rules of pharmaceuticals, aside from immunizations.”

Documented History on Immunizations

Concerning immunizations, Dr. Høeg has a more established, if troubling, history, Howard observe. She released a analysis using unverified crowd-sourced reports to determine the rate of myocarditis after COVID-19 vaccination. She counseled the state of Florida top health official Joseph Ladapo, who was said to have modified findings to imply COVID-19 vaccines are riskier than they are.

Among her “desired changes” for the current federal leadership included revising rules for novel immunizations and halting “non-essential” vaccines, she said after the election on a audio program. At the agency, Dr. Høeg has allegedly floated the idea of preventing young men from obtaining COVID-19 vaccinations.

“She is an thorough true believer who commences with her preconceived notions and reverse-engineers to fit the data in a very disingenuous, dishonest manner,” Dr. Howard said.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg aligned with fellow dissenters, {like|